I neonati e le sperimentazioni cliniche multiple

Avanti con prudenza

Translated title of the contribution: Newborns and multiple clinical experiments: Ahead with caution

Carlo Corchia, Andrea Dotta

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The frequency of randomized controlled trials on pharmacological therapies in newborn infants is going to increase following the active promotion initiatives of the European Community. Therefore, a high-risk baby might be eligible to participate in several research studies at the same time. Among the most important methodological and ethical aspects related to this possibility are the power of the studies, the interactions among treatments, the identification of side effects, the length of follow-up, the relationship with the parents and the expression of their consent; an important point is also the problem of possible claims for personal injuries following the clinical research. However, a methodologically appropriate and controlled experimentation of treatments, possibly under the verification and the guidance of well prepared and functioning Ethical Committees, is always better than the uncontrolled and unverified use of possibly efficacious but also possibly dangerous therapies.

Original languageItalian
Title of host publicationQuaderni ACP
Pages17-19
Number of pages3
Volume16
Edition1
Publication statusPublished - 2009

Fingerprint

Newborn Infant
European Union
Therapeutics
Research
Randomized Controlled Trials
Parents
Pharmacology
Wounds and Injuries

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Corchia, C., & Dotta, A. (2009). I neonati e le sperimentazioni cliniche multiple: Avanti con prudenza. In Quaderni ACP (1 ed., Vol. 16, pp. 17-19)

I neonati e le sperimentazioni cliniche multiple : Avanti con prudenza. / Corchia, Carlo; Dotta, Andrea.

Quaderni ACP. Vol. 16 1. ed. 2009. p. 17-19.

Research output: Chapter in Book/Report/Conference proceedingChapter

Corchia, C & Dotta, A 2009, I neonati e le sperimentazioni cliniche multiple: Avanti con prudenza. in Quaderni ACP. 1 edn, vol. 16, pp. 17-19.
Corchia C, Dotta A. I neonati e le sperimentazioni cliniche multiple: Avanti con prudenza. In Quaderni ACP. 1 ed. Vol. 16. 2009. p. 17-19
Corchia, Carlo ; Dotta, Andrea. / I neonati e le sperimentazioni cliniche multiple : Avanti con prudenza. Quaderni ACP. Vol. 16 1. ed. 2009. pp. 17-19
@inbook{46302d6e475744c2b101a571c5d62395,
title = "I neonati e le sperimentazioni cliniche multiple: Avanti con prudenza",
abstract = "The frequency of randomized controlled trials on pharmacological therapies in newborn infants is going to increase following the active promotion initiatives of the European Community. Therefore, a high-risk baby might be eligible to participate in several research studies at the same time. Among the most important methodological and ethical aspects related to this possibility are the power of the studies, the interactions among treatments, the identification of side effects, the length of follow-up, the relationship with the parents and the expression of their consent; an important point is also the problem of possible claims for personal injuries following the clinical research. However, a methodologically appropriate and controlled experimentation of treatments, possibly under the verification and the guidance of well prepared and functioning Ethical Committees, is always better than the uncontrolled and unverified use of possibly efficacious but also possibly dangerous therapies.",
keywords = "Clinical trials, High-risk newborn infants, Neonatology, Pharmacological therapies",
author = "Carlo Corchia and Andrea Dotta",
year = "2009",
language = "Italian",
volume = "16",
pages = "17--19",
booktitle = "Quaderni ACP",
edition = "1",

}

TY - CHAP

T1 - I neonati e le sperimentazioni cliniche multiple

T2 - Avanti con prudenza

AU - Corchia, Carlo

AU - Dotta, Andrea

PY - 2009

Y1 - 2009

N2 - The frequency of randomized controlled trials on pharmacological therapies in newborn infants is going to increase following the active promotion initiatives of the European Community. Therefore, a high-risk baby might be eligible to participate in several research studies at the same time. Among the most important methodological and ethical aspects related to this possibility are the power of the studies, the interactions among treatments, the identification of side effects, the length of follow-up, the relationship with the parents and the expression of their consent; an important point is also the problem of possible claims for personal injuries following the clinical research. However, a methodologically appropriate and controlled experimentation of treatments, possibly under the verification and the guidance of well prepared and functioning Ethical Committees, is always better than the uncontrolled and unverified use of possibly efficacious but also possibly dangerous therapies.

AB - The frequency of randomized controlled trials on pharmacological therapies in newborn infants is going to increase following the active promotion initiatives of the European Community. Therefore, a high-risk baby might be eligible to participate in several research studies at the same time. Among the most important methodological and ethical aspects related to this possibility are the power of the studies, the interactions among treatments, the identification of side effects, the length of follow-up, the relationship with the parents and the expression of their consent; an important point is also the problem of possible claims for personal injuries following the clinical research. However, a methodologically appropriate and controlled experimentation of treatments, possibly under the verification and the guidance of well prepared and functioning Ethical Committees, is always better than the uncontrolled and unverified use of possibly efficacious but also possibly dangerous therapies.

KW - Clinical trials

KW - High-risk newborn infants

KW - Neonatology

KW - Pharmacological therapies

UR - http://www.scopus.com/inward/record.url?scp=65249176177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249176177&partnerID=8YFLogxK

M3 - Capitolo

VL - 16

SP - 17

EP - 19

BT - Quaderni ACP

ER -